University Of Iowa Hosp & Clinics

Type: Teaching hospital
Where: Iowa City, IA
Medicare CCN: 160058
Received: $19,589,807 in 2,387 records, 2022 ($1,504,582 general, $18,085,224 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2022	General payment	261	$1,504,582
2022	Research payment	2,126	$18,085,224

By company

Company	Records	Amount	Years
PFIZER INC.	215	$3,444,005	2022
Merck Sharp & Dohme LLC	79	$2,920,132	2022
Boston Scientific Corporation	84	$1,027,281	2022
Cochlear Americas	41	$931,659	2022
Regeneron Pharmaceuticals, Inc.	110	$800,039	2022
Amgen Inc.	20	$773,895	2022
Novartis Pharmaceuticals Corporation	14	$687,859	2022
ABBVIE INC.	65	$615,335	2022
Edwards Lifesciences Corporation	21	$382,156	2022
Takeda Pharmaceuticals U.S.A., Inc.	50	$373,455	2022
SEAGEN INC.	93	$357,763	2022
E.R. Squibb & Sons, L.L.C.	24	$319,556	2022
Paragon 28, Inc.	13	$310,540	2022
Janssen Research & Development, LLC	40	$305,774	2022
JAZZ PHARMACEUTICALS INC.	2	$297,825	2022
Eli Lilly and Company	6	$291,525	2022
Boehringer Ingelheim Pharmaceuticals, Inc.	5	$262,846	2022
Sarepta Therapeutics, Inc.	122	$243,252	2022
Spark Therapeutics, Inc.	18	$236,487	2022
Genentech, Inc.	18	$225,786	2022
SANOFI US SERVICES INC.	22	$215,141	2022
BeiGene, Ltd.	17	$213,648	2022
Clovis Oncology, Inc.	14	$190,235	2022
MED-EL Corporation	6	$189,326	2022
AstraZeneca Pharmaceuticals LP	28	$186,825	2022
Novo Nordisk AS	262	$168,194	2022
DePuy Synthes Products, Inc.	2	$163,401	2022
PROGENICS PHARMACEUTICALS, INC.	12	$129,628	2022
PTC Therapeutics, Inc.	17	$128,904	2022
GENZYME CORPORATION	29	$120,445	2022
Intuitive Surgical, Inc.	12	$117,800	2022
Intercept Pharmaceuticals, Inc.	10	$115,334	2022
Medtronic, Inc.	11	$112,910	2022
Mannkind Corporation	5	$104,958	2022
Kite Pharma, Inc.	15	$100,540	2022
ARGENX US, INC.	21	$95,897	2022
Travere Therapeutics, Inc.	8	$93,297	2022
Ceribell, Inc.	1	$91,306	2022
ZOLL Medical Corporation	3	$91,271	2022
Roche Products Limited	10	$85,075	2022
Ascendis Pharma Endocrinology Inc	14	$81,947	2022
Stryker Corporation	5	$81,808	2022
Bolton Medical Inc	14	$78,979	2022
AstraZeneca UK Limited	5	$78,219	2022
Roche TCRC, Inc.	16	$74,490	2022
TRILLIUM THERAPEUTICS USA, LLC	16	$73,131	2022
CSL Behring	53	$70,811	2022
Celgene Corporation	3	$69,345	2022
Incyte Corporation	140	$66,467	2022
Mallinckrodt Hospital Products Inc.	10	$66,340	2022

By nature of payment

Nature	Records	Amount
Research payment	2,126	$18,085,224
Grant	35	$1,021,102
Space rental or facility fees (teaching hospital only)	134	$128,450
Consulting Fee	17	$127,696
Long term medical supply or device loan	13	$104,185
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	31	$67,903
Education	8	$30,019
Royalty or License	12	$17,109
Charitable Contribution	2	$2,789
Compensation for serving as faculty or as a speaker for a medical education program	1	$2,250
Travel and Lodging	1	$1,629
Debt forgiveness	2	$738
Food and Beverage	5	$709

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2022-12-31	Merck Sharp & Dohme LLC	$509,944	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Phase Ib study of Pembrolizumab and in-situ injection of CMP-001 in Patients with Relapsed and Refractory Lymphomas	2022
2022-12-31	Merck Sharp & Dohme LLC	$371,955	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N	2022
2022-12-31	Merck Sharp & Dohme LLC	$300,301	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N	2022
2022-12-31	Merck Sharp & Dohme LLC	$221,020	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba	2022
2022-12-31	Merck Sharp & Dohme LLC	$161,202	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv	2022
2022-12-31	Merck Sharp & Dohme LLC	$149,878	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy	2022
2022-12-31	Merck Sharp & Dohme LLC	$136,342	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With	2022
2022-12-31	Merck Sharp & Dohme LLC	$97,330	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary	2022
2022-12-31	Merck Sharp & Dohme LLC	$74,369	Research payment	Cash or cash equivalent	VERQUVO Drug, CARDIOVASCULAR	A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato	2022
2022-12-31	Merck Sharp & Dohme LLC	$60,145	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap	2022
2022-12-31	Merck Sharp & Dohme LLC	$57,692	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79	2022
2022-12-31	Merck Sharp & Dohme LLC	$54,655	Research payment	Cash or cash equivalent	Biological, CARDIOVASCULAR	A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for	2022
2022-12-31	Merck Sharp & Dohme LLC	$51,713	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection	2022
2022-12-31	Merck Sharp & Dohme LLC	$44,293	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Phase 1b,2 study of immune and targeted combination therapies in participants with RCC	2022
2022-12-31	Merck Sharp & Dohme LLC	$44,293	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B	2022
2022-12-31	Merck Sharp & Dohme LLC	$40,300	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera	2022
2022-12-31	Siemens Medical Solutions USA, Inc.	$40,250	Research payment	In-kind items and services	Artis Q floor Device, AT - Fixed interventional x-ray/angiography fluoroscopy	Iowa Ortega Neuro Clinical AT	2022
2022-12-31	Merck Sharp & Dohme LLC	$29,524	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N	2022
2022-12-31	Merck Sharp & Dohme LLC	$24,225	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With	2022
2022-12-31	Merck Sharp & Dohme LLC	$21,354	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A	2022
2022-12-31	Intuitive Surgical, Inc.	$21,050	Long term medical supply or device loan	In-kind items and services	DAVINCI XI Device, SURGERY		2022
2022-12-31	Merck Sharp & Dohme LLC	$20,611	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba	2022
2022-12-31	Merck Sharp & Dohme LLC	$16,798	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With	2022
2022-12-31	Merck Sharp & Dohme LLC	$10,636	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Phase 1b,2 study of immune and targeted combination therapies in participants with RCC	2022
2022-12-31	Merck Sharp & Dohme LLC	$10,636	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B	2022
2022-12-31	Merck Sharp & Dohme LLC	$8,741	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w	2022
2022-12-31	Merck Sharp & Dohme LLC	$8,693	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy	2022
2022-12-31	Merck Sharp & Dohme LLC	$8,324	Research payment	In-kind items and services	VERQUVO Drug, CARDIOVASCULAR	A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato	2022
2022-12-31	Merck Sharp & Dohme LLC	$7,761	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79	2022
2022-12-31	Merck Sharp & Dohme LLC	$7,454	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A	2022
2022-12-31	Merck Sharp & Dohme LLC	$7,410	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera	2022
2022-12-31	Merck Sharp & Dohme LLC	$7,332	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary	2022
2022-12-31	Merck Sharp & Dohme LLC	$6,825	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad	2022
2022-12-31	AstraZeneca Pharmaceuticals LP	$6,679	Research payment	In-kind items and services	IMFINZI Biological, Oncology	A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co	2022
2022-12-31	Merck Sharp & Dohme LLC	$6,348	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N	2022
2022-12-31	Merck Sharp & Dohme LLC	$6,323	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A	2022
2022-12-31	Merck Sharp & Dohme LLC	$6,248	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph	2022
2022-12-31	Merck Sharp & Dohme LLC	$6,210	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy	2022
2022-12-31	Merck Sharp & Dohme LLC	$5,860	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv	2022
2022-12-31	Merck Sharp & Dohme LLC	$5,641	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot	2022
2022-12-31	Intuitive Surgical, Inc.	$5,000	Education	In-kind items and services	DAVINCI XI Device, SURGERY		2022
2022-12-31	Merck Sharp & Dohme LLC	$4,794	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad	2022
2022-12-31	Monteris Medical Corporation	$4,300	Long term medical supply or device loan	Cash or cash equivalent	Neuroblate Device, Neuroblate		2022
2022-12-31	Merck Sharp & Dohme LLC	$3,994	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection	2022
2022-12-31	Merck Sharp & Dohme LLC	$3,977	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With	2022
2022-12-31	Intuitive Surgical, Inc.	$3,400	Long term medical supply or device loan	In-kind items and services	DAVINCI XI Device, SURGERY		2022
2022-12-31	Merck Sharp & Dohme LLC	$3,242	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w	2022
2022-12-31	Merck Sharp & Dohme LLC	$2,906	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79	2022
2022-12-31	Merck Sharp & Dohme LLC	$2,799	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224	2022
2022-12-31	Merck Sharp & Dohme LLC	$2,791	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair	2022
2022-12-31	Merck Sharp & Dohme LLC	$2,641	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot	2022
2022-12-31	Merck Sharp & Dohme LLC	$2,503	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224	2022
2022-12-31	Merck Sharp & Dohme LLC	$2,456	Research payment	In-kind items and services	VERQUVO Drug, CARDIOVASCULAR	A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato	2022
2022-12-31	Merck Sharp & Dohme LLC	$2,363	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad	2022
2022-12-31	ABBVIE INC.	$2,100	Research payment	In-kind items and services		A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Sma	2022
2022-12-31	Merck Sharp & Dohme LLC	$2,065	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair	2022
2022-12-31	Merck Sharp & Dohme LLC	$1,985	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph	2022
2022-12-31	Merck Sharp & Dohme LLC	$1,816	Research payment	In-kind items and services	WELIREG Drug, ONCOLOGY	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w	2022
2022-12-31	Merck Sharp & Dohme LLC	$1,647	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera	2022
2022-12-31	Merck Sharp & Dohme LLC	$1,568	Research payment	In-kind items and services	VERQUVO Drug, CARDIOVASCULAR	A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato	2022
2022-12-31	Linvatec Corporation	$1,098	Long term medical supply or device loan	In-kind items and services	AIRSEAL Device, GENERAL SURGERY		2022
2022-12-31	AstraZeneca Pharmaceuticals LP	$939	Research payment	In-kind items and services	LOKELMA Drug, Cardiovascular and Metabolism	Cardiovascular Renal and Metabolism Lokelma Hyperkalemia	2022
2022-12-31	AstraZeneca UK Limited	$704	Research payment	In-kind items and services	BYDUREON Drug, Cardiovascular and Metabolism	A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O	2022
2022-12-31	AstraZeneca Pharmaceuticals LP	$700	Research payment	In-kind items and services	FASENRA Biological, Respiratory	A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate th	2022
2022-12-31	Merck Sharp & Dohme LLC	$502	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for	2022
2022-12-31	Merck Sharp & Dohme LLC	$450	Research payment	In-kind items and services	VERQUVO Drug, CARDIOVASCULAR	A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out	2022
2022-12-31	Stryker Corporation	$438	Debt forgiveness	Cash or cash equivalent			2022
2022-12-31	KARL STORZ Endoscopy-America	$300	Debt forgiveness	In-kind items and services			2022
2022-12-31	Merck Sharp & Dohme LLC	$90	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with	2022
2022-12-31	KARL STORZ Endoscopy-America	$58	Long term medical supply or device loan	In-kind items and services			2022
2022-12-31	Merck Sharp & Dohme LLC	$27	Research payment	In-kind items and services	Biological, CARDIOVASCULAR	A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for	2022
2022-12-31	KARL STORZ Endoscopy-America	$22	Long term medical supply or device loan	In-kind items and services			2022
2022-12-31	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection	2022
2022-12-31	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	Phase 1b,2 study of immune and targeted combination therapies in participants with RCC	2022
2022-12-31	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B	2022
2022-12-31	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Epacadostat or Placebo in Combination With Pembrolizumab	2022
2022-12-30	Cochlear Americas	$81,080	Research payment	In-kind items and services	Cochlear Device, Implantable hearing solution	A post-approval, prospective, nonrandomized, single-arm multicenter investigation to evaluate the safety and effectivene	2022
2022-12-30	DePuy Synthes Products, Inc.	$41,833	Research payment	Cash or cash equivalent	FIBERGRAFT BG MORSELS Device, Spine	2018-0701	2022
2022-12-30	Mannkind Corporation	$14,094	Research payment	Cash or cash equivalent	AFREZZA Drug, DIABETES MEDICINE	INHALE-1	2022
2022-12-30	E.R. Squibb & Sons, L.L.C.	$8,847	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase III RCC Monotherapy vs. everolimus (ONO 4538-03) - A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Evero	2022
2022-12-28	BeiGene, Ltd.	$29,498	Research payment	Cash or cash equivalent		Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer	2022
2022-12-28	Intercept Pharmaceuticals, Inc.	$4,227	Research payment	Cash or cash equivalent		Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic	2022
2022-12-28	Elekta, Inc.	$3,600	Consulting Fee	Cash or cash equivalent	ELEKTA UNITY Device, LINAC SOLUTIONS (MR-LINAC)		2022
2022-12-28	Regeneron Pharmaceuticals, Inc.	$1,755	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS	2022
2022-12-23	SEAGEN INC.	$7,625	Research payment	Cash or cash equivalent		A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma	2022
2022-12-23	W. L. Gore & Associates, Inc.	$4,867	Research payment	Cash or cash equivalent	Product in Development Device, Devices	Gore CARDIOFORM Septal Occluder and Antiplatelet Medical Management for the Reduction of Recurrent Stroke in Patients wi	2022
2022-12-22	Cochlear Americas	$98,696	Research payment	Cash or cash equivalent		Cochlear Implant With Dexamethasone Eluting Electrode Array	2022
2022-12-22	Sarepta Therapeutics, Inc.	$15,296	Research payment	Cash or cash equivalent		SRP-5051-201	2022
2022-12-22	Regeneron Pharmaceuticals, Inc.	$5,648	Research payment	Cash or cash equivalent		AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBOD	2022
2022-12-22	Cochlear Americas	$5,250	Research payment	Cash or cash equivalent		Cochlear Implant With Dexamethasone Eluting Electrode Array	2022
2022-12-22	SEAGEN INC.	$4,399	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$4,018	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$4,018	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	Janssen Research & Development, LLC	$3,942	Research payment	Cash or cash equivalent	CARVYKTI Drug, Oncology	A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B	2022
2022-12-22	Sarepta Therapeutics, Inc.	$3,890	Research payment	Cash or cash equivalent		SRP-5051-201	2022
2022-12-22	SEAGEN INC.	$2,578	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$2,578	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$2,072	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$2,072	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$478	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	Cochlear Americas	$310	Research payment	In-kind items and services		Cochlear Implant With Dexamethasone Eluting Electrode Array	2022
2022-12-22	SEAGEN INC.	$131	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$131	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$131	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$131	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$131	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$131	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-22	SEAGEN INC.	$131	Research payment	Cash or cash equivalent	ADCETRIS Biological, Oncology	A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies	2022
2022-12-21	Cochlear Americas	$78,176	Research payment	Cash or cash equivalent	Cochlear Device, Implantable hearing solution	A post-approval, prospective, nonrandomized, single-arm multicenter investigation to evaluate the safety and effectivene	2022
2022-12-21	PFIZER INC.	$6,501	Research payment	Cash or cash equivalent		AN OPENLABEL STUDY IN ADOLESCENT AND ADULT SEVERE COAGULATION FACTOR ACTIVITY 1 HEMOPHILIA A OR B PATIENTS WITH OR WITHO	2022
2022-12-21	Novo Nordisk AS	$6,205	Research payment	Cash or cash equivalent	Wegovy Drug, Obesity	EX9536-4388	2022
2022-12-21	ABBVIE INC.	$4,154	Research payment	Cash or cash equivalent	HUMIRA Biological, IMMUNOLOGY	A Long-Term Registry of Humira?? (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)	2022
2022-12-21	Takeda Pharmaceuticals U.S.A., Inc.	$3,369	Research payment	Cash or cash equivalent		A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	2022
2022-12-21	Takeda Pharmaceuticals U.S.A., Inc.	$2,600	Research payment	Cash or cash equivalent		A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	2022
2022-12-21	Novo Nordisk AS	$1,789	Research payment	Cash or cash equivalent	Sogroya Biological, Growth Hormone	NN8640-4263	2022
2022-12-21	Regeneron Pharmaceuticals, Inc.	$1,777	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF	2022
2022-12-21	Takeda Pharmaceuticals U.S.A., Inc.	$1,642	Research payment	Cash or cash equivalent		A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	2022
2022-12-21	SEAGEN INC.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	TUKYSA Drug, Oncology		2022
2022-12-21	Takeda Pharmaceuticals U.S.A., Inc.	$1,202	Research payment	Cash or cash equivalent		A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	2022
2022-12-21	Cochlear Americas	$810	Research payment	In-kind items and services		Cochlear Implant With Dexamethasone Eluting Electrode Array	2022
2022-12-21	Leadiant Biosciences, Inc.	$12	Research payment	Cash or cash equivalent	Drug, Neuromuscular Disease	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with G	2022
2022-12-21	Sarepta Therapeutics, Inc.	$11	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$10	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$9	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$7	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$7	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$5	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$3	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$1	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$1	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$0	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-21	Sarepta Therapeutics, Inc.	$0	Research payment	Cash or cash equivalent		SRP-9001-301	2022
2022-12-20	Cochlear Americas	$28,350	Research payment	In-kind items and services		Cochlear Implant With Dexamethasone Eluting Electrode Array	2022
2022-12-20	Janssen Research & Development, LLC	$3,848	Research payment	Cash or cash equivalent		Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase	2022
2022-12-20	PFIZER INC.	$3,733	Research payment	Cash or cash equivalent		A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED	2022
2022-12-20	PFIZER INC.	$2,906	Research payment	Cash or cash equivalent		A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461	2022
2022-12-20	Novartis Pharmaceuticals Corporation	$2,338	Research payment	Cash or cash equivalent		A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY A	2022
2022-12-20	ABBVIE INC.	$1,000	Research payment	Cash or cash equivalent	MAVYRET Drug, VIROLOGY	A Single-Arm Retrospective Study to Evaluate Safety and Efficacy in Patients with Acute Hepatitis C Virus (HCV) Infectio	2022
2022-12-20	PFIZER INC.	$486	Research payment	Cash or cash equivalent		A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE	2022
2022-12-19	Merck Sharp & Dohme LLC	$54,124	Research payment	Cash or cash equivalent	WELIREG Drug, ONCOLOGY	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w	2022
2022-12-19	Janssen Research & Development, LLC	$37,247	Research payment	Cash or cash equivalent	CARVYKTI Drug, Oncology	A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu	2022
2022-12-19	SANOFI US SERVICES INC.	$6,695	Research payment	Cash or cash equivalent	KEVZARA Biological, Rheumatology	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With G	2022
2022-12-19	Janssen Research & Development, LLC	$4,990	Research payment	Cash or cash equivalent	CARVYKTI Drug, Oncology	A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu	2022
2022-12-19	Boston Scientific Corporation	$4,735	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	ACURATE IDE	2022
2022-12-19	Boston Scientific Corporation	$2,280	Research payment	Cash or cash equivalent	GENERAL - THERAPIES Device, THERAPIES	INTERRUPT AF	2022
2022-12-19	Boston Scientific Corporation	$1,627	Research payment	Cash or cash equivalent	WATCHMAN Access System Device, STRUCTURAL HEART	CHAMPIONAF	2022
2022-12-19	ICU Medical Inc	$700	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Non-dedicated sets Device, Infusion		2022
2022-12-19	SANOFI US SERVICES INC.	$574	Research payment	Cash or cash equivalent		A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Fact	2022
2022-12-16	PFIZER INC.	$3,733	Research payment	Cash or cash equivalent		A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED	2022
2022-12-16	ARGENX US, INC.	$3,027	Research payment	Cash or cash equivalent	VYVGART Drug, Immunology	A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg	2022
2022-12-16	SEAGEN INC.	$1,950	Research payment	Cash or cash equivalent		A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma	2022
2022-12-16	Regeneron Pharmaceuticals, Inc.	$858	Research payment	Cash or cash equivalent	DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA	2022
2022-12-16	Astellas Pharma US Inc	$700	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2022
2022-12-15	PFIZER INC.	$7,466	Research payment	Cash or cash equivalent		A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED	2022
2022-12-15	Medtronic, Inc.	$4,873	Research payment	Cash or cash equivalent	ONYX 18 Device, Liquid Embolics	EMBOLISE	2022
2022-12-15	Osteogenics Biomedical Inc.	$4,219	Education	In-kind items and services			2022
2022-12-15	PFIZER INC.	$1,034	Research payment	Cash or cash equivalent	COMIRNATY Biological, VACCINES	A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT	2022
2022-12-14	Regeneron Pharmaceuticals, Inc.	$20,655	Research payment	Cash or cash equivalent		A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects W	2022
2022-12-14	Mannkind Corporation	$3,000	Research payment	Cash or cash equivalent	AFREZZA Drug, DIABETES MEDICINE	INHALE-1	2022
2022-12-13	SEAGEN INC.	$7,500	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$4,331	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,439	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,350	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,196	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,119	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,119	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$2,119	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$1,450	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$1,450	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$299	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	SEAGEN INC.	$299	Research payment	Cash or cash equivalent	TUKYSA Drug, Oncology	A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer	2022
2022-12-13	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent	Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent	Rivacor 7 DR-T Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent	Solia Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent	Solia Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$277	Research payment	Cash or cash equivalent	Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$180	Research payment	Cash or cash equivalent	Sentus Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$180	Research payment	Cash or cash equivalent	Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$180	Research payment	Cash or cash equivalent	Solia Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$180	Research payment	Cash or cash equivalent	Plexa ProMRI Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	Novo Nordisk AS	$83	Research payment	In-kind items and services	Wegovy Drug, Obesity	EX9536-4388	2022
2022-12-13	BIOTRONIK INC.	$75	Research payment	Cash or cash equivalent	Sentus Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$75	Research payment	Cash or cash equivalent	Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022
2022-12-13	BIOTRONIK INC.	$75	Research payment	Cash or cash equivalent	Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases	BIO-LIBRA	2022

The latest 200 records of 2,387.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Iowa City, IA, county Johnson County, IA, state Iowa; placed by its city name.

Measure	Place (city or town) Iowa City, IA	County Johnson County, IA	State Iowa
Population B01003	75,752	156,639	3,210,507
Population, 2020 census P1	74,828	152,854	3,190,369
Median age B01002	26.2	31.0	38.6
Under 18 B01001	14.3%	19.3%	22.9%
65 and over B01001	12.3%	13.3%	18.1%
Households B11001	30,816	63,341	1,315,707
Foreign born B05002	12.2%	9.8%	5.9%
Median household income B19013	$58,546	$74,935	$75,059
Median family income B19113	$111,960	$118,607	$97,491
Per capita income B19301	$37,842	$45,136	$40,877
Poverty rate B17001	26.3%	17.1%	11.1%
Unemployment rate B23025	4.6%	3.8%	3.6%
Civilian labor force B23025	45,244	90,024	1,699,994
Mean commute (minutes) B08013	17.3	19.4	19.8
Bachelor's degree or higher B15003	60.5%	55.2%	31.4%
Housing units B25001	33,863	68,217	1,437,699
Owner-occupied B25003	47.2%	59.4%	71.7%
Renters B25003	52.8%	40.6%	28.3%
Median home value B25077	$285,900	$308,600	$208,000
Median gross rent B25064	$1,094	$1,122	$972
White, not Hispanic B03002	70.4%	74.8%	82.3%
Black B03002	9.4%	7.6%	3.8%
Hispanic or Latino B03002	8.1%	6.7%	7.3%
Asian B03002	7.1%	5.6%	2.5%
American Indian and Alaska Native B03002	0.0%	0.1%	0.2%

Economy now FRED unemployment 3.2% in Sep 2026 (3.4% a year earlier); per capita personal income $67,321 in 2025, up 28% in five years (+2.8% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Iowa City, IA.